People · Operator

Dean Schorno

Named in public records as an officer, director or promoter · active 2015–2015 · Biotechnology

1
Companies
3
Filings
$614.0M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Adaptive Biotechnologies CorpBiotechnologySeries D+$614.0M$8.0B2015
Operator network

Dean Schorno at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Chad Robins · 5 companies · 1 sharedChad RobinsLee Huntsman · 5 companies · 1 sharedLee HuntsmanArnold Levine · 4 companies · 1 sharedArnold LevinePeter Neupert · 4 companies · 1 sharedPeter NeupertJohn Stuelpnagel · 3 companies · 1 sharedJohn StuelpnagelChad Cohen · 2 companies · 1 sharedChad CohenChris Carlson · 2 companies · 1 sharedChris CarlsonCraig Weissman · 2 companies · 1 sharedCraig WeissmanHarlan Robins · 2 companies · 1 sharedHarlan RobinsTom Willis · 2 companies · 1 sharedTom WillisAndris Zoltners · 1 companies · 1 sharedAndris ZoltnersAndy Zoltners · 1 companies · 1 sharedAndy ZoltnersKathleen Determann · 1 companies · 1 sharedKathleen DetermannRob Hershberg · 1 companies · 1 sharedRob HershbergRob Rosen · 1 companies · 1 sharedRob RosenAdaptive Biotechnologies Corp · $614.0M raisedAdaptive Biotechnolog…Dean SchornoDS
Dean Schorno Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Dean Schorno on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Lee Huntsman15
Chad Robins15
Arnold Levine14
Peter Neupert14
John Stuelpnagel13
Chad Cohen12
Harlan Robins12
Chris Carlson12
Tom Willis12
Craig Weissman12
Andris Zoltners11
Andy Zoltners11
Rob Hershberg11
Rob Rosen11
Kathleen Determann11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.